Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biotech company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming BofA Securities 2025 Healthcare Conference. The company's management will deliver a presentation on Tuesday, May 13, 2025, at 1:40 p.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website at www.akerotx.com, where an archived replay will also be available after the presentation.

News Market Reaction

-0.93%

1 alert

-0.93% News Effect

On the day this news was published, AKRO declined 0.93%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:
Christina Tartaglia
Precision AQ
332.322.7430
Christina.tartaglia@precisionaq.com

Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com

FAQ

When is Akero Therapeutics (AKRO) presenting at the BofA Securities Healthcare Conference 2025?

Akero Therapeutics will present at the BofA Securities Healthcare Conference on Tuesday, May 13, 2025, at 1:40 p.m. Pacific Time.

How can I watch Akero Therapeutics' (AKRO) presentation at the BofA Securities conference?

The presentation can be accessed through a live webcast on Akero's investor relations website at www.akerotx.com. An archived replay will also be available after the event.

What type of company is Akero Therapeutics (AKRO)?

Akero Therapeutics is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.

Where can I find the replay of Akero Therapeutics' (AKRO) BofA Securities conference presentation?

The archived replay of the presentation will be available on Akero's company website at www.akerotx.com in the investor relations section.